Literature DB >> 8798495

Identification and characterization of two alternative splice variants of human interleukin-2.

V N Tsytsikov1, V V Yurovsky, S P Atamas, W J Alms, B White.   

Abstract

Our previous work showed that alternative splicing is used to make an inhibitory variant of human interleukin (IL)-4. Because of homology between IL-4 and IL-2 proteins and receptors, we tested whether alternative splicing is used to generate similar inhibitory variants of human IL-2. Messenger RNA from peripheral blood mononuclear cells was subjected to reverse transcription-polymerase chain reaction using IL-2 exon 1- and exon 4-specific primers. Two amplification products, named IL-2delta2 and IL-2delta3, were found in addition to the native IL-2 product. The IL-2delta2 cDNA sequence was identical to IL-2 cDNA throughout the entire coding region, except exon 2 was omitted by alternative splicing. In IL-2delta3 cDNA, the third exon of IL-2 was omitted by alternative splicing. Unlike IL-2, IL-2delta2 and IL-2delta3 did not stimulate T cell proliferation. However, both inhibited IL-2 costimulation of T cell proliferation, and both inhibited cellular binding of rhIL-2 to high affinity IL-2 receptors. Thus, IL-2 is the second cytokine that uses alternative splicing to generate variants that are competitive inhibitors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8798495     DOI: 10.1074/jbc.271.38.23055

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Interleukin 4 in systemic sclerosis: not just an increase.

Authors:  S P Atamas; B White
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

2.  The usefulness of competitive PCR: airway gene expression of IL-5, IL-4, IL-4delta2, IL-2, and IFNgamma in asthma.

Authors:  E M Glare; M Divjak; M J Bailey; E H Walters
Journal:  Thorax       Date:  2001-07       Impact factor: 9.139

Review 3.  IL-2 and Beyond in Cancer Immunotherapy.

Authors:  John M Wrangle; Alicia Patterson; C Bryce Johnson; Daniel J Neitzke; Shikhar Mehrotra; Chadrick E Denlinger; Chrystal M Paulos; Zihai Li; David J Cole; Mark P Rubinstein
Journal:  J Interferon Cytokine Res       Date:  2018-02       Impact factor: 2.607

4.  Characterization of alternatively spliced transcript variants of CLEC2D gene.

Authors:  Claire Germain; Franck Bihl; Stefan Zahn; Gwenola Poupon; Marie-Jeanne Dumaurier; Hariniaina Henintsoa Rampanarivo; Søren Berg Padkjær; Pieter Spee; Veronique M Braud
Journal:  J Biol Chem       Date:  2010-09-14       Impact factor: 5.157

5.  Splice variants of mda-7/IL-24 differentially affect survival and induce apoptosis in U2OS cells.

Authors:  Erin L Whitaker; Valery Filippov; Maria Filippova; Christian F Guerrero-Juarez; Penelope J Duerksen-Hughes
Journal:  Cytokine       Date:  2011-08-16       Impact factor: 3.861

6.  The IL-2/CD25 pathway determines susceptibility to T1D in humans and NOD mice.

Authors:  Calliope A Dendrou; Linda S Wicker
Journal:  J Clin Immunol       Date:  2008-09-09       Impact factor: 8.317

7.  Tuberculosis-induced variant IL-4 mRNA encodes a cytokine functioning as growth factor for (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate-specific Vgamma2Vdelta2 T cells.

Authors:  ZhuQing Yuan; Richard Wang; Yuyang Lee; Crystal Y Chen; XingBing Yu; ZhongDao Wu; Dan Huang; Ling Shen; Zheng W Chen
Journal:  J Immunol       Date:  2009-01-15       Impact factor: 5.422

8.  An activation-induced IL-15 isoform is a natural antagonist for IL-15 function.

Authors:  Lei Zhao; Bo Hu; Yinsheng Zhang; Yuan Song; Dandan Lin; Yonghao Liu; Yu Mei; Dedy Sandikin; Weiping Sun; Min Zhuang; Haiyan Liu
Journal:  Sci Rep       Date:  2016-05-11       Impact factor: 4.379

9.  EV-3, an endogenous human erythropoietin isoform with distinct functional relevance.

Authors:  Christel Bonnas; Liane Wüstefeld; Daniela Winkler; Romy Kronstein-Wiedemann; Ekrem Dere; Katja Specht; Melanie Boxberg; Torsten Tonn; Hannelore Ehrenreich; Herbert Stadler; Inge Sillaber
Journal:  Sci Rep       Date:  2017-06-16       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.